Moderate and Severe RheumatoId Arthritis
2
0
0
1
Key Insights
Highlights
Success Rate
50% trial completion
Treatment Research
2 treatments under study, led by Placebo Plus Mtx
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 80/100
50.0%
1 terminated out of 2 trials
50.0%
-36.6% vs benchmark
50%
1 trials in Phase 3/4
0%
0 of 1 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 1 completed trials
Clinical Trials (2)
A Study of the Efficacy and Safety of TACI-antibody Fusion Protein Injection (RC18) in Subjects with Inadequate Response to MTX Due to Treat Moderate and Severe Rheumatoid Arthritis.
A Study of the Efficacy and Safety of TACI-antibody Fusion Protein Injection (RC18) in Subjects With Inadequate Response to TNF-α Antagonists Due to Treat Moderate and Severe Rheumatoid Arthritis
Research Network
Common Treatments
- Placebo Plus Mtx2
- Rc18 160 Mg Plus Mtx2
Active Sponsors
- RemeGen Co., Ltd.2
Top Investigators
Peking Union Medical College Hospital
RenJi Hospital